Detailed price information for Jasper Therapeutics Inc. (JSPR-Q) from The Globe and Mail including charting and trades.
REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
The presentation slides and a link to the live and archived webcast will also be available on the Events & News - Events page of Jasper's Investor Relations website. Jasper is a clinical-stage ...
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ...
8don MSN
Rethinking long-term allergy treatments: Experimental vaccine protects against anaphylaxis in mice
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...
Investing.com -- Jasper Therapeutics Inc (NASDAQ:JSPR) stock surged 17.4% in premarket trading Tuesday after the clinical-stage biotech company reported positive preliminary data from its ETESIAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback